ATE423127T1 - Peptidinhibitoren der ns3-protease des hepatoitis c virus - Google Patents
Peptidinhibitoren der ns3-protease des hepatoitis c virusInfo
- Publication number
- ATE423127T1 ATE423127T1 AT99955475T AT99955475T ATE423127T1 AT E423127 T1 ATE423127 T1 AT E423127T1 AT 99955475 T AT99955475 T AT 99955475T AT 99955475 T AT99955475 T AT 99955475T AT E423127 T1 ATE423127 T1 AT E423127T1
- Authority
- AT
- Austria
- Prior art keywords
- protease
- virus
- hepatoitis
- peptide inhibitors
- terminus
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- VIUCNIMDPZQXAD-UHFFFAOYSA-N 2-azaniumyl-4,4-difluorobutanoate Chemical compound OC(=O)C(N)CC(F)F VIUCNIMDPZQXAD-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 abstract 1
- 108700012707 hepatitis C virus NS3 Proteins 0.000 abstract 1
- 150000004715 keto acids Chemical group 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9812523.0A GB9812523D0 (en) | 1998-06-10 | 1998-06-10 | Peptide inhibitors of hepatitis c virus ns3 protease |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE423127T1 true ATE423127T1 (de) | 2009-03-15 |
Family
ID=10833529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99955475T ATE423127T1 (de) | 1998-06-10 | 1999-06-09 | Peptidinhibitoren der ns3-protease des hepatoitis c virus |
Country Status (9)
Country | Link |
---|---|
US (1) | US6867284B1 (de) |
EP (1) | EP1084137B1 (de) |
JP (1) | JP2002517508A (de) |
AT (1) | ATE423127T1 (de) |
AU (1) | AU754773B2 (de) |
CA (1) | CA2330247A1 (de) |
DE (1) | DE69940429D1 (de) |
GB (1) | GB9812523D0 (de) |
WO (1) | WO1999064442A1 (de) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA979327B (en) | 1996-10-18 | 1998-05-11 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
AU2001245356A1 (en) | 2000-02-29 | 2001-09-12 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
IL151934A0 (en) * | 2000-04-05 | 2003-04-10 | Schering Corp | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
NZ521456A (en) | 2000-04-19 | 2004-07-30 | Schering Corp | Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties |
BR0112666A (pt) * | 2000-07-21 | 2003-06-10 | Schering Corp | Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
DK1385870T3 (da) | 2000-07-21 | 2010-07-05 | Schering Corp | Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US6653295B2 (en) | 2000-12-13 | 2003-11-25 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
HUP0400726A3 (en) | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
KR100926244B1 (ko) | 2001-07-11 | 2009-11-12 | 버텍스 파마슈티칼스 인코포레이티드 | 브릿지된 바이사이클릭 세린 프로테아제 억제제 |
ES2323451T7 (es) * | 2001-07-20 | 2011-08-01 | Psychogenics Inc. | Tratamiento para el trastorno de hiperactividad con deficit de atencion. |
AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
AU2002348414B2 (en) | 2001-10-24 | 2009-10-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
EP2468744A2 (de) | 2002-04-11 | 2012-06-27 | Vertex Pharmaceuticals Incorporated | Inhibitoren der Serinproteasen, insbesondere der HCV-NS3-NS4A-Protease |
US6878722B2 (en) | 2002-05-20 | 2005-04-12 | Bristol-Myers Squibb Company | Substituted cycloalkyl P1′ hepatitis C virus inhibitors |
AU2003299519A1 (en) | 2002-05-20 | 2004-05-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
AU2003248535A1 (en) | 2002-05-20 | 2003-12-12 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis c virus inhibitors |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
EP1454627A1 (de) * | 2003-03-06 | 2004-09-08 | MyoContract Ltd. | Alpha-Keto-Carbonyl-Verbindungen als Calpainhemmer |
BRPI0410456B8 (pt) | 2003-05-21 | 2021-05-25 | Boehringer Ingelheim Int | compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação |
TWI359147B (en) | 2003-09-05 | 2012-03-01 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv n |
AU2004274051A1 (en) | 2003-09-22 | 2005-03-31 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
AU2004282148A1 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
CN102020697B (zh) | 2003-10-14 | 2014-10-29 | F·霍夫曼-罗须公司 | 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺 |
WO2005040142A1 (en) | 2003-10-24 | 2005-05-06 | Aventis Pharmaceuticals Inc. | Novel keto-oxadiazole derivatives as cathepsin inhibitors |
WO2005043118A2 (en) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
EP1944042A1 (de) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Kombinationen für die HCV-Behandlung |
AU2004285019B9 (en) | 2003-10-27 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | HCV NS3-NS4A protease resistance mutants |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2005049622A1 (ja) * | 2003-11-19 | 2005-06-02 | Japan Tobacco Inc. | 5-5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途 |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2549851C (en) | 2004-01-21 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
CA2554999A1 (en) | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
EP1719773B1 (de) | 2004-02-24 | 2009-04-15 | Japan Tobacco, Inc. | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor |
CA2568379A1 (en) | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
EP1773355B1 (de) | 2004-06-24 | 2014-06-25 | Merck Sharp & Dohme Corp. | Nukleosid-aryl-phosporamidate zur behandlung von rna-abhängiger rna-viralinfektion |
CA2573346C (en) | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
AU2005291918A1 (en) | 2004-10-01 | 2006-04-13 | Vertex Pharmaceuticals Incorporated | HCV NS3-NS4A protease inhibition |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
WO2006119061A2 (en) | 2005-05-02 | 2006-11-09 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
KR101294467B1 (ko) | 2005-07-25 | 2013-09-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 거대고리형 억제제 |
US8278322B2 (en) | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
ES2401661T3 (es) * | 2005-08-02 | 2013-04-23 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas |
JP2009513564A (ja) | 2005-08-09 | 2009-04-02 | メルク エンド カムパニー インコーポレーテッド | Rna依存性rnaウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体 |
KR20130038947A (ko) | 2005-08-19 | 2013-04-18 | 버텍스 파마슈티칼스 인코포레이티드 | 방법 및 중간체 |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
AU2006301966A1 (en) | 2005-10-11 | 2007-04-19 | Array Biopharma, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
EP2392590A3 (de) | 2005-11-11 | 2012-03-14 | Vertex Pharmaceuticals Incorporated | Hepatitis-C-Virusvarianten |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
KR20080112303A (ko) | 2006-03-16 | 2008-12-24 | 버텍스 파마슈티칼스 인코포레이티드 | 중수소화 c형 간염 프로테아제 억제제 |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
EP1886685A1 (de) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors |
AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
US8309540B2 (en) | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
CA2667146C (en) | 2006-10-24 | 2016-01-19 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
CA2667031C (en) | 2006-10-27 | 2013-01-22 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
CN101568346B (zh) | 2006-10-27 | 2015-11-25 | 默沙东公司 | Hcv ns3蛋白酶抑制剂 |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
JP2010513450A (ja) | 2006-12-20 | 2010-04-30 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 抗ウイルス性インドール |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
KR20090115970A (ko) * | 2007-02-27 | 2009-11-10 | 버텍스 파마슈티칼스 인코포레이티드 | 공-결정 및 그를 포함하는 제약 조성물 |
CA2679426A1 (en) * | 2007-02-27 | 2008-09-04 | Luc Farmer | Inhibitors of serine proteases |
EP2494991A1 (de) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Kombinationstherapie zur Behandlung von HIV-Infektionen |
AR068794A1 (es) | 2007-06-29 | 2009-12-09 | Gilead Sciences Inc | Compuestos antivirales |
AP2874A (en) | 2007-06-29 | 2014-03-31 | Gilead Sciences Inc | Antiviral compounds |
WO2009010785A1 (en) | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
US8927569B2 (en) | 2007-07-19 | 2015-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as antiviral agents |
JP5443360B2 (ja) | 2007-08-30 | 2014-03-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | 共結晶体およびそれを含む医薬組成物 |
GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
EP2234977A4 (de) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | Viren-polymerasehemmer |
FR2927900B1 (fr) * | 2008-02-27 | 2010-09-17 | Clariant Specialty Fine Chem | Procede de preparation d'alpha-aminoacetals optiquement actifs. |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
WO2009134624A1 (en) | 2008-04-28 | 2009-11-05 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
PL2540350T3 (pl) | 2008-07-22 | 2014-10-31 | Merck Sharp & Dohme | Kombinacje makrocyklicznego związku chinoksaliny, który jest inhibitorem proteazy NS3 HCV z innymi środkami przeciw HCV |
AU2010203656A1 (en) | 2009-01-07 | 2011-07-21 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of HCV and HIV infection |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
EP2459582B1 (de) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Hvc-ns3-proteasehemmer |
CN101723896B (zh) * | 2009-11-03 | 2012-10-31 | 山东大学 | 酪氨酸衍生物类组蛋白去乙酰化酶抑制剂及其应用 |
AU2011209051B2 (en) | 2010-01-27 | 2015-01-15 | AB Pharma Ltd. | Polyheterocyclic compounds highly potent as HCV inhibitors |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
WO2012171332A1 (zh) | 2011-06-16 | 2012-12-20 | 爱博新药研发(上海)有限公司 | 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用 |
US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
WO2013106344A1 (en) | 2012-01-12 | 2013-07-18 | Ligand Pharmaceuticals, Inc. | 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5' |
WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
EP2899207A1 (de) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | Neues Verfahren zum Testen von HCV-Proteasehemmung |
AU2015217221A1 (en) | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
GB2563396B (en) | 2017-06-12 | 2020-09-23 | Ustav Organicke Chemie A Biochemie Av Cr V V I | Inhibitors of Rhomboid Intramembrane Proteases |
EP3737676B1 (de) | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Acetalverbindungen und therapeutische verwendungen davon |
KR20210098504A (ko) | 2018-12-04 | 2021-08-10 | 브리스톨-마이어스 스큅 컴퍼니 | 다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법 |
GB202010989D0 (en) * | 2020-07-16 | 2020-09-02 | Rosalind Franklin Inst | Photoredox protein modification |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2250232A1 (en) * | 1996-04-03 | 1997-10-09 | Allen I. Oliff | A method of treating cancer |
EP0907659A1 (de) | 1996-05-10 | 1999-04-14 | Schering Corporation | Hepatitis c virus ns3 protease synthetische inhibitoren |
ZA979327B (en) * | 1996-10-18 | 1998-05-11 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
-
1998
- 1998-06-10 GB GBGB9812523.0A patent/GB9812523D0/en not_active Ceased
-
1999
- 1999-06-09 EP EP99955475A patent/EP1084137B1/de not_active Expired - Lifetime
- 1999-06-09 DE DE69940429T patent/DE69940429D1/de not_active Expired - Fee Related
- 1999-06-09 AU AU42798/99A patent/AU754773B2/en not_active Ceased
- 1999-06-09 JP JP2000553450A patent/JP2002517508A/ja active Pending
- 1999-06-09 CA CA002330247A patent/CA2330247A1/en not_active Abandoned
- 1999-06-09 US US09/719,261 patent/US6867284B1/en not_active Expired - Fee Related
- 1999-06-09 AT AT99955475T patent/ATE423127T1/de not_active IP Right Cessation
- 1999-06-09 WO PCT/GB1999/001824 patent/WO1999064442A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP2002517508A (ja) | 2002-06-18 |
EP1084137B1 (de) | 2009-02-18 |
CA2330247A1 (en) | 1999-12-16 |
EP1084137A1 (de) | 2001-03-21 |
US6867284B1 (en) | 2005-03-15 |
GB9812523D0 (en) | 1998-08-05 |
WO1999064442A1 (en) | 1999-12-16 |
AU754773B2 (en) | 2002-11-21 |
DE69940429D1 (de) | 2009-04-02 |
AU4279899A (en) | 1999-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE423127T1 (de) | Peptidinhibitoren der ns3-protease des hepatoitis c virus | |
DE122012000004I1 (de) | Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus. | |
BG103392A (en) | Serine protease inhibitors, in particular of hepatitis with virus ns3 protease | |
ATE430166T1 (de) | Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus | |
ATE317854T1 (de) | Hepatitis c inhibitor peptide | |
NZ503263A (en) | Hepatitis C NS3 protease inhibitor peptides and peptide analogues | |
ATE469914T1 (de) | Peptide als hemmer der serinprotease des hepatitis c virus | |
ATE357511T1 (de) | Dipeptidylpeptidasen | |
HUP9901725A2 (hu) | Szubtilizinváltozatok | |
ATE385253T1 (de) | Nhibitor-resistente hcv ns3 protease | |
AU6162999A (en) | Apoptosis marker antibodies and methods of use | |
MXPA02001307A (es) | Deteccion de micro-organismos. | |
NO960939L (no) | Kininogenaseinhibitor | |
EP1209233A3 (de) | Alkalische Proteasen | |
SI0932617T1 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease | |
PT830130E (pt) | Enzima de conversao de tnf-alfa | |
AU2126400A (en) | Detection of small molecules by use of a piezoelectric sensor | |
EP1347044A3 (de) | Alkalische Protease | |
DE60034888D1 (de) | N-substituierte l-aminosäuren enthaltende peptide, zur prävention der beta-strang assoziation | |
WO2003002730A3 (fr) | Methode de detection de l'activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite methode | |
ATE385805T1 (de) | Neue peptide | |
BR9710965A (pt) | Detergentes contendo enzima protease e enzima loccase | |
DE69812597D1 (de) | Peptide zur Inhibition von HPV E7 Proteinen | |
TH48056A3 (th) | สารผสมดูแลสำหรับการดูแลส่วนตัวที่มีเอนไซม์ สับทิลิซิน ที่ถูกจับยึดไว้กับซับสเตรทที่ไม่ละลายในน้ำ | |
ATE344277T1 (de) | Peptide aus dem b-glycoprotein des menschlichen herpesvirus-7, besonders anwendbar bei serologischen elisa-nachweisen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |